Scienture (NASDAQ:SCNX – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Volatility and Risk
Scienture has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500.
Earnings and Valuation
This table compares Scienture and Gyre Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scienture | $430,000.00 | 343.66 | -$41.51 million | ($2.10) | -1.71 |
| Gyre Therapeutics | $116.59 million | 6.80 | $5.03 million | ($0.21) | -33.86 |
Gyre Therapeutics has higher revenue and earnings than Scienture. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
5.7% of Scienture shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 19.5% of Scienture shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for Scienture and Gyre Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scienture | 1 | 1 | 1 | 0 | 2.00 |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
Scienture presently has a consensus target price of $37.50, suggesting a potential upside of 941.96%. Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 125.04%. Given Scienture’s stronger consensus rating and higher probable upside, analysts plainly believe Scienture is more favorable than Gyre Therapeutics.
Profitability
This table compares Scienture and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scienture | N/A | -53.51% | -42.47% |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
Summary
Scienture beats Gyre Therapeutics on 7 of the 13 factors compared between the two stocks.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
